A Prospective, Randomized, Controlled Phase II Clinical Study of Trilaciclib Combined With Standard Treatment Project As a Neoadjuvant Treatment For Triple Negative Breast Cancer

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 26 Jul 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Cyclophosphamide (Primary) ; Epirubicin (Primary) ; Paclitaxel (Primary) ; Trilaciclib (Primary)
Indications Chemotherapy induced febrile neutropenia
Focus Adverse reactions

21 Jul 2023 Planned initiation date changed from 30 Jun 2023 to 30 Jul 2023.
19 May 2023 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com